Get Live Data

PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

  2. Share Prices
  3. Physiomics Share Price
  4. Physiomics Share Regulatory News
  5. Dispatch of Annual Report and Shareholder Circular

Pin to quick picksPhysiomics Regulatory News (PYC)

Physiomics Information

Share Price Information for Physiomics (PYC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.25
Bid: 1.10
Ask: 1.40
Change: 0.00 (0.00%)
Spread: 0.30 (27.273%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.25
PYC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Dispatch of Annual Report and Shareholder Circular

15 Oct 2018 13:00

RNS Number : 0587E
Physiomics PLC
15 October 2018
 

 

 

Physiomics plc

("Physiomics") or ("the Company")

 

Dispatch of Annual Report and Shareholder Circular

 

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has today posted to shareholders

- its Annual Report for the financial year ended 30th June 2018 and

- a Circular in relation to its forthcoming Annual General Meeting

 

As previously announced on the 8th October 2018, the Company's Annual General Meeting will be held at 10:00 a.m. on 20th November 2018 at the Company's registered office, The Magdalen Centre, Oxford Science Park, Robert Robinson Avenue, Oxford, OX4 4GA.

 

A copy of the Circular containing further details of the resolutions as well as a copy of the Company's Annual Report will be made available today on the Company's website at https://www.physiomics-plc.com/investors/investors-news-rns/. 

 

 

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

WH Ireland Limited (nomad)

Katy Mitchell

+44 (0) 161 832 2174

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCLLFVIIFLELIT
123456789
Date   Source Headline
31st Mar 20167:00 amRNSHeads of Terms with BioMoti and Board Changes
22nd Dec 201512:08 pmRNSIssue of Options
22nd Dec 20157:00 amRNSNew Speciality Pharma Customer for New Indication
18th Dec 201510:57 amRNSPlacing
14th Dec 201510:29 amRNSResult of General Meeting
4th Dec 201511:38 amRNSResult of AGM
27th Nov 20154:15 pmRNSNotice of General Meeting
10th Nov 20157:00 amRNSFinal Results
6th Nov 20157:00 amRNSStrategic Update
12th Oct 20157:00 amRNS4th Large Pharma Customer for Virtual Tumour
9th Oct 20157:00 amRNSProject extension with global pharma company
4th Aug 20157:01 amRNSProf. Mark Middleton appointed to Physiomics SAB
29th Apr 20154:27 pmRNSHolding(s) in Company
22nd Apr 20157:00 amRNSVirtual Tumour platform - AACR Annual Meeting 2015
26th Mar 20157:00 amRNSIssue of Options
17th Mar 20157:00 amRNSHalf Yearly Report
12th Mar 20157:00 amRNSIssue of Equity
6th Mar 20151:40 pmRNSHolding(s) in Company
4th Mar 201511:56 amRNSHolding(s) in Company
3rd Mar 201512:57 pmRNSFirst contract for clinical version of Virtu
20th Feb 201512:34 pmRNSHolding(s) in Company
2nd Feb 20157:00 amRNSTermination of Equity Swap Agreement
15th Dec 20141:08 pmRNSResult of AGM
12th Nov 201410:24 amRNSFinal Results
4th Nov 20147:00 amRNSDisclosure of Large Pharma partner Merck & Co
27th Oct 201410:07 amRNSProject extension with global pharma company
13th Oct 20144:43 pmRNSHolding(s) in Company
7th Oct 20149:35 amRNSCardiotox Platform Launch
29th Aug 20142:47 pmRNSHolding(s) in Company
14th Aug 20141:10 pmRNSNew deal with global pharma
24th Jul 201412:59 pmRNSIssue of Equity
26th Jun 20147:57 amRNSHolding(s) in Company
12th Jun 20147:00 amRNSAnticipated new collaboration with Diatech
20th May 20149:47 amRNSHolding(s) in Company
10th Apr 20147:00 amRNSSecond validation of Virtual Tumour Clinical
14th Feb 20147:00 amRNSHalf Yearly Report
30th Jan 20144:41 pmRNSIssue of Equity - Replacement
30th Jan 20143:02 pmRNSIssue of Equity
16th Jan 20147:20 amRNSDundee University Collaboration
17th Dec 20132:07 pmRNSResult of AGM
4th Dec 201310:47 amRNSVirtual Tumour Proposal
28th Nov 20131:24 pmRNSDrugCARD launch
15th Nov 20137:00 amRNSFinal Results
11th Nov 20137:00 amRNSUniversity of Oxford Collaboration
4th Nov 20137:00 amRNSUpdate on the Virtual Tumour Clinical platform
10th Oct 201310:30 amRNSDrawdown pursuant to SEDA Arrngmnt/Issue of Equity
7th Oct 20138:32 amRNSPhysiomics gains new speciality pharma customer
1st Oct 201311:49 amRNSPhysiomics gains first large pharma customer
16th Sep 20137:00 amRNSPhysiomics to present cardiac toxicity platform
26th Jul 20131:30 pmRNSIssue of Equity
123456789

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.